|
ES2032831T5
(es)
|
1986-08-19 |
2001-02-16 |
Genentech Inc |
Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
|
|
JPH01215289A
(ja)
|
1988-02-22 |
1989-08-29 |
Toa Nenryo Kogyo Kk |
遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
|
|
FR2649991B2
(fr)
|
1988-08-05 |
1994-03-04 |
Rhone Poulenc Sante |
Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
|
|
US5728553A
(en)
|
1992-09-23 |
1998-03-17 |
Delta Biotechnology Limited |
High purity albumin and method of producing
|
|
KR100384353B1
(ko)
|
1994-05-18 |
2003-10-04 |
네크타르 테라퓨틱스 |
인터페론의건조분말제형을제조하기위한방법및조성물
|
|
DE4417598A1
(de)
|
1994-05-19 |
1995-12-14 |
Max Planck Gesellschaft |
Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
|
|
WO1996023879A1
(en)
|
1995-01-30 |
1996-08-08 |
Terrapin Technologies, Inc. |
Glubodies - multiplicities of proteins capable of binding a variety of small molecules
|
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
|
DE19641876B4
(de)
|
1996-10-10 |
2011-09-29 |
Iba Gmbh |
Streptavidinmuteine
|
|
WO1998016873A1
(en)
|
1996-10-14 |
1998-04-23 |
Firm Forsat Ltd. |
Method for preparing dispersions of chromogenic components
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
CA2233725A1
(en)
|
1998-03-31 |
1999-09-30 |
Hemosol Inc. |
Hemoglobin-hydroxyethyl starch complexes
|
|
DK1087778T3
(da)
|
1998-06-08 |
2005-12-19 |
Hoffmann La Roche |
Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
|
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
|
DE19926068C1
(de)
|
1999-06-08 |
2001-01-11 |
Arne Skerra |
Muteine des Bilin-Bindungsproteins
|
|
US7235520B2
(en)
|
2000-09-21 |
2007-06-26 |
University Of Massachusetts |
Method of inducing apoptosis in lymphoid cells
|
|
CA2440582A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
|
WO2003029462A1
(en)
*
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
US7118915B2
(en)
|
2001-09-27 |
2006-10-10 |
Pieris Proteolab Ag |
Muteins of apolipoprotein D
|
|
WO2005019255A1
(en)
|
2003-08-25 |
2005-03-03 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
|
WO2005019254A1
(en)
|
2003-08-25 |
2005-03-03 |
Pieris Proteolab Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
JP2007284351A
(ja)
|
2004-07-27 |
2007-11-01 |
Osaka Bioscience Institute |
アミロイド蛋白質の凝集を抑制する物質とその作用
|
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
ES2373055T3
(es)
*
|
2005-08-09 |
2012-01-31 |
Oncotherapy Science, Inc. |
Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
|
|
US20070191272A1
(en)
|
2005-09-27 |
2007-08-16 |
Stemmer Willem P |
Proteinaceous pharmaceuticals and uses thereof
|
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
EP1996613B1
(en)
*
|
2006-03-20 |
2014-04-30 |
Technische Universität München |
Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
|
|
WO2007137170A2
(en)
|
2006-05-20 |
2007-11-29 |
Seattle Genetics, Inc. |
Anti-glypican-3 antibody drug conjugates
|
|
CA2659413C
(en)
|
2006-08-01 |
2016-06-14 |
Pieris Ag |
Muteins of tear lipocalin and methods for obtaining the same
|
|
AU2008275985B2
(en)
|
2007-07-17 |
2013-09-19 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against Glypican-3
|
|
WO2009052390A1
(en)
|
2007-10-19 |
2009-04-23 |
Abbott Laboratories |
Glycosylated mammalian ngal and use thereof
|
|
EP2313430B1
(en)
|
2008-06-24 |
2018-05-02 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
|
EP2990798B1
(en)
*
|
2009-12-07 |
2019-09-25 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
|
|
JP2013529907A
(ja)
|
2010-05-24 |
2013-07-25 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
Ｎｇａｌタンパク質変異体及びその使用
|
|
PL2580236T3
(pl)
|
2010-06-08 |
2019-09-30 |
Pieris Pharmaceuticals Gmbh |
Muteiny lipokaliny łez wiążące IL-4 R alfa
|
|
AU2011290751B2
(en)
|
2010-08-16 |
2015-08-13 |
Pieris Ag |
Binding proteins for Hepcidin
|
|
CA2817779C
(en)
|
2010-11-15 |
2019-02-19 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
US20130225505A1
(en)
|
2011-11-23 |
2013-08-29 |
Allergan, Inc. |
Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
CA2891557A1
(en)
*
|
2013-03-26 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
MX384075B
(es)
|
2015-01-28 |
2025-03-14 |
Pieris Pharmaceuticals Gmbh |
Nuevas proteínas específicas para la angiogénesis.
|
|
WO2016131804A1
(en)
|
2015-02-18 |
2016-08-25 |
Sanofi |
Novel proteins specific for pyoverdine and pyochelin
|
|
ES2932425T3
(es)
|
2015-05-04 |
2023-01-19 |
Pieris Pharmaceuticals Gmbh |
Proteínas específicas para CD137
|
|
BR112017020961A2
(pt)
|
2015-05-18 |
2018-07-10 |
Pieris Pharmaceuticals Gmbh |
muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
|